<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815360</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00002813</org_study_id>
    <nct_id>NCT00815360</nct_id>
  </id_info>
  <brief_title>Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion</brief_title>
  <acronym>RaScaL</acronym>
  <official_title>Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Associates of Florida, P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Associates of Florida, P.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of ranibizumab and angiographically-directed peripheral scatter laser
      therapy in patients with clinically-significant diabetic macular edema (CSME) and peripheral
      nonperfusion. We propose a novel treatment of CSME in a subgroup of patients defined by a
      combination of ultrawide-field angiography (UWFA) and optical coherence tomography (OCT).
      Within this classification scheme, patients with CSME are subdivided by the presence of: 1)
      focal macular leakage, 2) vitreomacular interface traction, and/or 3) peripheral
      nonperfusion. The successful treatment of diabetic macular edema would be dictated by
      pathophysiology-directed therapy based on this classification.

      The subgroup of interest for this clinical trial is characterized by diabetic macular edema,
      peripheral nonperfusion on UWFA, and the absence of macular traction on OCT. This group of
      patients has previously not been well recognized or characterized due to limitations in
      previous, standard angiographic evaluation of the retinal periphery.

      We postulate that this subcategory represents one with a high rate of failure of accepted
      therapies given persistence of the basic pathophysiologic mechanism for CSME, namely
      ischemia-induced production of Vascular Endothelial Growth Factor (VEGF) from the retinal
      periphery. This also represents a population of patients with likely recurrence of CSME
      despite treatment with anti-VEGF therapy alone for the same reason.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy is a leading cause of moderate and severe visual loss in developed
      countries. It is of paramount socioeconomic impact as the prevalence of diabetes is sharply
      increasing, diabetic macular edema is the leading cause of vision loss in working age
      patients, it is a significant cause of vision loss in patients older than 65 years of age, it
      frequently affects patients bilaterally, and the costs of therapy are increasing.

      Diabetic macular edema (DME) is the most common cause of vision loss in diabetic retinopathy.
      The pathophysiology of DME is complex and multifactorial. Chronic hyperglycemia, protein
      kinase C (PKC) formation, free radical accumulation, advanced glycation end-product (AGE)
      proteins, and ischemia-driven release of vascular endothelial growth factor (VEGF) are some
      of the better understood factors that contribute to chronic retinal arterial and capillary
      damage and increased permeability.

      The RIDE and RISE Studies demonstrated the superiority of anti-VEGF monotherapy with
      ranibizumab over sham therapy, when all groups were allowed to receive macular laser therapy
      after month 3 based on predefined criteria. Furthermore, other studies have demonstrated VEGF
      inhibitors to be beneficial for DME, either as monotherapy or in combination with macular
      laser.

      The benefit of VEGF antagonists in treating DME validates that the VEGF pathway is a key
      target. The need for repeated anti-VEGF injections to maintain the benefit of treatment begs
      the question whether persistent peripheral retinal ischemia may be driving VEGF production in
      at least a subset of patients with DME. Fluorescein angiographic studies of the mid- and
      far-periphery of diabetic patients by Shimizu in the 1980's demonstrated areas of peripheral
      retinal nonperfusion in diabetic patients. These findings have been reproduced and
      substantiated more recently utilizing a novel, commercially-available imaging system for
      ultrawide-field angiography (UWFA) that employs a scanning laser ophthalmoscope and an
      ellipsoidal mirror.

      We investigated whether patients with diabetic macular edema associated with peripheral
      nonperfusion on UWFA would have improved visual acuity, resolution of retinal thickening on
      OCT, and durability of therapy using a novel strategy of a single intravitreal injection of
      Ranibizumab, a VEGF-A inhibitor + UWFA-guided peripheral Scatter Laser, or RaScaL. A second
      goal of the study was to guide DME treatment by the imaging signature of UWFA and OCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)
peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)
macular laser per treatment criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of ranibizumab</intervention_name>
    <description>intravitreal injection of 0.5 mg ranibizumab</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral laser</intervention_name>
    <description>ultra-widefield fluorescein angiography guided peripheral laser</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of triamcinolone acetonide</intervention_name>
    <description>intravitreal injection of 4.0 mg triamcinolone acetonide</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>control arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>macular laser</intervention_name>
    <description>macular laser to areas of retinal thickening or leakage</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible if the following criteria are met:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 18 years

        Patient related considerations:

        • Patients with Type I or Type II diabetes

        Disease related considerations:

          -  Study eye with clinically significant diabetic macular edema characterized by macular
             edema, peripheral nonperfusion, and absence of macular traction on clinical exam,
             UWFA, and OCT.

          -  Study eye with best corrected visual acuity between 20/40 (≤ 73 letters on Early
             Treatment of Diabetic Retinopathy Study (ETDRS) chart and 20/320 (≥ 19 letters on
             ETDRS chart) Other considerations

          -  Patient able to complete all study visits

          -  Female patients must be using two forms of contraception

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or lactation. Premenopausal women not using
             adequate contraception. The following are considered effective means of contraception:
             surgical sterilization or use of oral contraceptives, barrier contraception with
             either a condom or diaphragm in conjunction with spermicidal gel, an Intra Uterine
             Device, or contraceptive hormone implant or patch.

          -  Prior enrollment in the study

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  Therapy with intravitreal triamcinolone, pegaptanib, ranibizumab, or bevacizumab
             within the previous 3 months

          -  Previous panretinal scatter laser photocoagulation

          -  Previous pars plana vitrectomy

          -  Visually-significant significant cataracts as primary reason for vision loss

          -  Uncontrolled or advanced glaucoma

          -  Patients on more than one anti-glaucoma agent

          -  Myocardial infarction or cerebrovascular accident within 6 months

          -  Subjects with poor glycemic control that have initiated intensive insulin treatment or
             plan to do so in the next 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan J Suner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Associates of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Associates of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <results_first_submitted>May 23, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2015</results_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Associates of Florida, P.A.</investigator_affiliation>
    <investigator_full_name>Ivan J. Suner, MD</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>diabetic macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on Ultra Widefield Fluorescein Angiography (UWFA).</recruitment_details>
      <pre_assignment_details>Treatment naive patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>ranibizumab and scatter laser</description>
        </group>
        <group group_id="P2">
          <title>Comparative Group 1</title>
          <description>Intravitreal triamcinolone with macular laser</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group 1</title>
          <description>ranibizumab and scatter laser</description>
        </group>
        <group group_id="B2">
          <title>Comparative Group 1</title>
          <description>Intravitreal triamcinolone with macular laser</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="7.5"/>
                    <measurement group_id="B2" value="58.3" spread="6.5"/>
                    <measurement group_id="B3" value="58.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.</title>
        <time_frame>6 months</time_frame>
        <population>We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on UWFA.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>ranibizumab and scatter laser</description>
          </group>
          <group group_id="O2">
            <title>Comparative Group 1</title>
            <description>Intravitreal triamcinolone with macular laser</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.</title>
          <population>We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on UWFA.</population>
          <units>Letters of visual acuity on ETDRS chart</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9" upper_limit="15"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>ranibizumab and scatter laser</description>
          </group>
          <group group_id="O2">
            <title>Comparative Group 1</title>
            <description>Intravitreal triamcinolone with macular laser</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months</title>
          <units>units on a scale (microns)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="240" upper_limit="310"/>
                    <measurement group_id="O2" value="350" lower_limit="280" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group 1</title>
          <description>Intravitreal ranibizumab and peripheral laser</description>
        </group>
        <group group_id="E2">
          <title>Comparative Group 1</title>
          <description>Intravitreal triamcinolone acetonide and macular laser</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small study size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ivan J. Suner</name_or_title>
      <organization>Retina Associates of Florida, P.A.</organization>
      <phone>813-875-6373</phone>
      <email>ivansuner@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

